Biogen to Acquire RayThera, Bolstering Immunology Pipeline with Potential $1 Billion Deal
Money

Biogen to Acquire RayThera, Bolstering Immunology Pipeline with Potential $1 Billion Deal

authorBy Dave Ramsey
DateJun 18, 2026
Read Time2 min

Biogen Inc. recently confirmed its agreement to acquire the private biotechnology firm RayThera Inc. for a transaction valued at up to $1 billion. This strategic maneuver is set to significantly broaden Biogen's immunology portfolio and extend its reach into new therapeutic areas.

The agreement outlines an initial payment to RayThera's shareholders, with a substantial portion of the total consideration contingent upon the achievement of future clinical and regulatory milestones. This acquisition is projected to conclude in the third quarter of 2026.

RayThera specializes in the discovery and development of small-molecule treatments for immunological diseases. Its current pipeline includes several anti-inflammatory programs designed to address various immune-mediated conditions. The company anticipates its leading candidate will progress into Phase 1 development in early third quarter of 2026.

In recent years, Biogen has garnered considerable attention for its Alzheimer's disease research initiatives. In May, the company released top-line Phase 2 data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide therapy for early Alzheimer's. While the study did not meet its primary endpoint, the data revealed cognitive benefits and reductions in tau biomarkers. In other recent corporate developments, Biogen bolstered its pipeline through the acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, aiming to enhance its growth in immunology and rare diseases. Additionally, in April, Biogen entered into a collaboration with Alloy Therapeutics Inc. to accelerate the development of antisense therapies for various undisclosed conditions, with Alloy receiving an upfront payment and potential future milestone payments and royalties.

Biogen's strategic acquisition of RayThera underscores its unwavering commitment to advancing medical science and addressing unmet patient needs. By integrating RayThera's innovative pipeline, Biogen is poised to deliver groundbreaking therapies that can alleviate suffering and improve the lives of countless individuals globally, fostering hope and progress in the battle against complex diseases.

More Articles
Money
CarMax Q1 Boost: Analyst Seeks More Evidence for Long-Term Growth
CarMax has reported a strong first quarter, driven by market share gains and operational efficiencies, leading to improved retail gross profit per unit. However, an analyst from Needham, Chris Pierce, maintains a 'Hold' rating on the stock, citing concerns about the sustainability of unit growth and potential competitive pressures from rivals like Carvana.
By Natalie PaceJun 18, 2026
Money
Costco Stock: Evaluating Its Position Amidst Market Dynamics
Costco's stock is currently trading around $985, a valuation that suggests strong operational performance, yet faces pressure from a tightening economic climate and persistent inflation. The company's unique membership model continues to drive revenue and membership growth, but its high price-to-earnings ratio warrants careful consideration for potential investors. The Federal Reserve's stance on inflation adds another layer of complexity, influencing market multiples for even top-tier retailers.
By T. Harv EkerJun 18, 2026
Money
ServiceNow: A Leading AI Software Investment
ServiceNow is gaining significant attention as a prime investment in generative AI software. With strong analyst ratings and a promising outlook, the company is expanding its partnership with IBM to enhance AI capabilities. This collaboration aims to modernize enterprise systems and leverage AI for advanced IT operations, positioning ServiceNow for substantial growth in the evolving tech landscape.
By Natalie PaceJun 18, 2026
Money
Insuring the Future: Space AI Data Centers Seek Coverage
Space startups, including those backed by industry giants like SpaceX and Blue Origin, are engaging with insurance providers to secure coverage for their proposed orbital AI data centers. This burgeoning sector, seen by some as the future of AI development, faces challenges in valuation and risk modeling due to the novel nature of placing sophisticated AI hardware in the harsh space environment. Preliminary discussions are underway, highlighting the critical need for insurance to attract the necessary financing for these ambitious ventures to move from concept to reality.
By Chika UwazieJun 18, 2026
Money
Grocery Chain Shutting Down Two Long-Standing Stores
A grocery chain with a 91-year history is closing two of its long-standing California stores, impacting local communities. These closures are attributed to persistent underperformance despite previous investments in upgrades. The wider grocery industry is grappling with increasing operational costs, supply chain challenges, and intense competition, leading many retailers to reevaluate their physical presence.
By Natalie PaceJun 18, 2026